EGCG, the main compound in green tea, offers modest, well-supported improvements in cholesterol, blood pressure, blood sugar, and fat burning — mostly for those already working on these markers. Longevity, cancer, and brain benefits remain unproven in people. Its main serious concern is dose-dependent liver injury, worst at high doses on an empty stomach. (Full Review)

Protocol

Standard Dose

200–400 mg/day

Standardized green tea extract; keep well below the 800 mg/day caution threshold

Timing & Food

With a meal

Never fasted; morning or midday for caffeinated products

Form

Extract or brewed tea

Or ~3–5 cups green tea; split higher totals into two doses with meals

Time to effect

Cholesterol

Weeks–months

Lipid changes need several weeks to a few months of consistent intake

Blood Sugar & Pressure

Weeks–months

Cardiometabolic changes build over several weeks to a few months

Fat Burning & Alertness

Within hours

Thermogenic and alertness effects appear acutely

Benefits

High: Improved blood lipid profile

Medium: Enhanced fat oxidation and modest weight reduction; improved glycemic control; modest blood pressure and endothelial improvement

Low: Cancer chemoprevention; acute cognitive and mood effects

Speculative: Longevity and healthspan signaling; neuroprotection

Contraindications

Bortezomib

Active or prior liver disease or persistently elevated liver enzymes

Pregnancy or breastfeeding

Iron-deficiency anemia (with meals)

Key Interactions

Beta-blockers (nadolol, atenolol)

Statins (atorvastatin, rosuvastatin, simvastatin)

Folate, methotrexate

Anticoagulants, antiplatelets (aspirin, warfarin)

Other hepatotoxic agents (acetaminophen, high-dose niacin, alcohol)

Iron and mineral supplements

Additive or absorption-altering agents (berberine, verapamil)

Risk & Side Effects

High: Hepatotoxicity

Medium: Gastrointestinal distress; reduced non-heme iron absorption

Low: Caffeine-related stimulant effects

Speculative: High-dose pro-oxidant and thyroid effects; antiplatelet and bleeding potential

Monitoring

Marker	Target	Why
ALT	~10–25 U/L	Detects liver injury, the primary risk
AST	~10–25 U/L	Complements ALT for liver-cell stress
LDL cholesterol	<100 mg/dL	Tracks the most consistent benefit
Fasting glucose	75–90 mg/dL	Tracks glycemic benefit
HbA1c	<5.4%	Captures longer-term blood-sugar effect
Ferritin	~50–100 ng/mL	Flags iron depletion from catechin binding
Blood pressure	<120/80 mmHg	Tracks the modest cardiovascular effect

Cadence: Baseline, then 4–8 weeks after starting, then every 6–12 months during use; test promptly if liver-stress symptoms appear

Qualitative Assessment

Energy and perceived alertness through the day
Sleep quality (especially with caffeinated products)
Absence of digestive upset, dark urine, or right-upper-abdominal discomfort
General sense of well-being and exercise tolerance

EGCG for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment